14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $883M | $78M | 0.0% | 12.6% | 14.4% | 5.4% | $171M | $309M | $286M |
| 2024 | $614M | -$19M | 0.0% | 0.1% | -4.7% | -1.5% | $48M | $318M | $145M |
| 2023 | $487M | $19M | 0.0% | 9.6% | 4.4% | 2.1% | $110M | $286M | $221M |
| 2022 | $316M | -$48M | 0.0% | -11.2% | -15.3% | -6.3% | -$40M | $287M | $48M |
| 2021 | $216M | -$43M | 0.0% | -18.4% | -12.9% | -5.6% | $765000 | $287M | $100M |
| 2020 | $208M | -$23M | 58.2% | -7.7% | -11.5% | -4.9% | $9M | $186M | $8M |
| 2019 | $207M | $6M | 69.4% | 7.9% | 2.9% | 1.3% | $39M | $186M | $62M |
| 2018 | $202M | $15M | 63.8% | 17.5% | 7.9% | 3.6% | $61M | $71M | $43M |
| 2017 | $177M | -$1M | 55.3% | 16.0% | -0.6% | -0.3% | $29M | $128M | $31M |
| 2016 | $129M | $4M | 62.1% | 15.6% | 2.3% | 1.2% | $23M | $121M | $27M |
| 2015 | — | $15M | — | — | 9.6% | 5.4% | $15M | $113M | $155M |
| 2014 | — | $29M | — | — | 20.6% | 11.1% | $21M | $107M | $169M |
| 2013 | — | $301000 | — | — | 0.7% | 0.7% | -$6M | — | $11M |
| 2012 | — | -$2M | — | — | 3.5% | -11.0% | -$429000 | — | $11000 |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $266M | $25M | 0.0% | 15.2% | 4.1% | 1.7% | $54M | $301M | $360M |
| Mar '26 | $237M | $29M | 0.0% | 16.4% | 5.2% | 2.1% | $52M | $305M | $311M |
| Dec '25 | $247M | $27M | 0.0% | 14.1% | 5.1% | 1.9% | $29M | $309M | $286M |
| Sep '25 | $228M | $27M | 0.0% | 15.9% | 5.3% | 1.9% | $38M | $313M | $263M |
| Jun '25 | $211M | $9M | 0.0% | 6.6% | 2.0% | 0.6% | $72M | $315M | $218M |
| Mar '25 | $197M | $16M | 0.0% | 13.3% | 3.7% | 1.2% | $33M | $316M | $150M |
| Dec '24 | $191M | -$10M | 0.0% | -2.3% | -2.5% | -0.8% | $13M | $318M | $145M |
| Sep '24 | $148M | -$24M | 0.0% | -13.8% | -6.0% | -1.9% | $8M | $320M | $145M |
| Jun '24 | $138M | -$2M | 0.0% | 3.7% | -0.5% | -0.2% | $13M | $285M | $240M |
| Mar '24 | $137M | $18M | 0.0% | 14.8% | 4.0% | 2.0% | $14M | $285M | $229M |
| Dec '23 | $132M | $1M | 0.0% | 5.1% | 0.3% | 0.1% | $42M | $286M | $221M |
| Sep '23 | $132M | $10M | 0.0% | 13.6% | 2.3% | 1.1% | $30M | $286M | $193M |
| Jun '23 | $117M | $6M | 0.0% | 10.6% | 1.5% | 0.7% | $18M | $286M | $162M |
| Mar '23 | $107M | $1M | 0.0% | 9.3% | 0.5% | 0.2% | $19M | $286M | $68M |
| Dec '22 | $94M | -$4M | 0.0% | 1.9% | -1.4% | -0.6% | -$8M | $287M | $48M |
| Sep '22 | $84M | -$9M | 0.0% | -6.0% | -2.8% | -1.2% | $1M | $287M | $56M |
| Jun '22 | $74M | -$15M | 0.0% | -17.5% | -4.8% | -2.0% | -$13M | $287M | $63M |
| Mar '22 | $64M | -$20M | 0.0% | -29.8% | -6.3% | -2.7% | -$21M | $287M | $77M |
| Dec '21 | $61M | -$24M | 0.0% | -38.9% | -7.2% | -3.1% | -$13M | $287M | $100M |
| Sep '21 | $52M | -$4M | 0.0% | -6.8% | -2.3% | -0.9% | -$6M | $202M | $15M |
How the market has priced ANIP against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Ani Pharmaceuticals Inc's revenue has grown 33.5% per year. These are computed facts, not advice.
As of FY2025, Ani Pharmaceuticals Inc reported $309M of total debt against $286M of cash.
In FY2025, gross margin was —, operating margin 12.6%, and net margin 8.8%.
As of Sep '26, Ani Pharmaceuticals Inc traded at a price-to-earnings ratio of about 19.4× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.